Abstract
Diabetes mellitus (DM) may cause an increase in the inflammatory status and oxidative stress as well as sympathetic nervous system overactivity, even in the absence of any other organic heart disease. We investigated the effect of perindopril, an angiotensin-converting enzyme inhibitor (ACE-i), on indexes of systemic inflammation and oxidative stress in normotensive patients with type 2 DM. We also examined the effect of the drug on the disturbances of left ventricular myocardial adrenergic innervation that may be seen in these patients. We studied 62 normotensive patients with type 2 DM, who were randomized to receive perindopril (n=32) or placebo (n=30). At the start of the study and after 6 months' therapy blood samples were taken to evaluate total peroxides (TP), interleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α), and the patients underwent a 123I-metaiodobenzylguanidine myocardial scintigraphy study. ACE-i caused a significant reduction in levels of cytokines and TP (P<0.001 for IL-6 and TNF-α, P=0.001 for TP). There was also a reduction in total defect score (P<0.001) and the heart to mediastinum ratio at 10 min and 4 h was improved (P<0.001 for both). No significant alterations were observed in the placebo group. Our data indicate that the addition of ACE-i to the medication of normotensive diabetic type 2 patients may improve the disturbed myocardial adrenergic innervation, the systemic inflammatory status and oxidative stress. Our findings indicate the cardioprotective action of ACE-i and suggest that earlier treatment might be appropriate in those patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Beckman JA, Goldfine AB, Gordon MB, Creager MA . Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. Circulation 2001; 103: 1618–1623.
Pickup JC . Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004; 27: 813–882.
Libby P . Changing concepts of atherogenesis. J Intern Med 2000; 247: 349–358.
Straub RH, Linde H, Mannel DN, Scholmerich J, Falk W . A bacteria-induced switch of sympathetic effector mechanisms augments local inhibition of TNF-α and IL-6 secretion in the spleen. FASEB J 2000; 14: 1380–1388.
Opere CA, Opere D, Ohia SE . Mechanism of peroxide-induced potentiation of sympathetic neurotransmission in bovine irides: role of extracellular calcium. Free Radic Res 1998; 28: 283–292.
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G . Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–153.
Yasuda G, Hasegawa K, Kuji T, Ogawa N, Shimura G, Umemura S et al. Perindopril effects on ambulatory blood pressure: relation to sympathetic nervous activity in subjects with diabetic nephropathy. Am J Hypertens 2004; 17: 14–20.
Manolis AJ, Iraklianou S, Pittaras A, Zairis M, Tsioufis K, Psaltiras G et al. Arterial compliance changes in diabetic normotensive patients after angiotensin-converting enzyme inhibition therapy. Am J Hypertens 2005; 18: 18–22.
World Health Organization Study Group. Diabetes Mellitus, Technical report series no. 727 Geneva: World Health Organization, 1985.
Ridker PM, Rifai N, Stampfer MJ, Hennekens CH . Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767–1772.
Ikeda U, Ito T, Shimada K . Interleukin-6 and acute coronary syndrome. Clin Cardiol 2001; 24: 701–704.
Pliquett RU, Fasshauer M, Bluher M, Paschke R . Neurohumoral stimulation in type-2-diabetes as an emerging disease concept. Cardiovasc Diabetol 2004; 3: 4.
Paulson DJ, Light KE . Elevation of serum and ventricular norepinephrine content in the diabetic rat. Res Commun Chem Pathol Pharmacol 1981; 33: 559–562.
Schnell O, Muhr D, Weiss M, Kirsch C, Haslbeck M, Tatsch K et al. Three-year follow-up on scintigraphically assessed cardiac sympathetic denervation in patients with long-term insulin-dependent (type I) diabetes mellitus. J Diab Complications 1997; 5: 307–313.
Nagamachi S, Fujita S, Nishii R, Futami S, Tamura S, Mizuta M et al. Prognostic value of cardiac I-123 metaiodobenzylguanidine imaging in patients with non–insulin-dependent diabetes mellitus. J Nucl Cardiol 2006; 13: 34–42.
Hesse B, Meyer C, Nielsen FS, Sato A, Hove JD, Holm S et al. Myocardial perfusion in type 2 diabetes with left ventricular hypertrophy: normalisation by acute angiotensin-converting enzyme inhibition. Eur J Nucl Med Mol Imaging 2004; 31: 362–368.
Weiss D, Sorescu Taylor WR . Angiotensin II and atherosclerosis. Am J Cardiol 2001; 87: 25C–32C.
Koh KK, Ahn JY, Han SH, Kim DS, Jin DK, Shin MS et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003; 42: 905–910.
Takeda T, Hoshida S, Nishino M, Tanouchi J, Otsu K, Hori M . Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. Atherosclerosis 2003; 169: 155–158.
Kontopoulos AG, Athyros VG, Didangelos TP . Effects of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy. Diab Care 1997; 20: 355–361.
Nagamachi S, Fujita S, Nishii R, Futami S, Tamura S, Mizuta M et al. Prognostic value of cardiac I-123 metaiodobenzylguanidine imaging in patients with non–insulin-dependent diabetes mellitus. J Nucl Cardiol 2006; 13: 34–42.
Story DF, Ziogas J . Interaction of angiotensin with noradrenergic neuroeffector transmission. Trends Pharmacol Sci 1987; 8: 269–271.
Esler M . Differentiation in the effects of the angiotensin II receptor blocker class on autonomic function. J Hypertens 2002; 20: S13–S19.
Malik KU . Prostaglandins-modulation of adrenergic nervous system. Fed Proc 1978; 37: 203–207.
Schmidt A, Grossmann G, Hauner H, Koenig W, Jansen T, Stauch M et al. Left ventricular function and wall thickness in long-term insulin-dependent diabetes mellitus: an echocardiographic study. J Int Med 1991; 229: 527–531.
Waeber B, Nussberger J, Perret L, Santoni JP, Brunner HR . Experience with perindopril in normal volunteers. Clin Exp Hypertens A 1989; 11: 507–519.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Marketou, M., Zacharis, E., Koukouraki, S. et al. Effect of angiotensin-converting enzyme inhibitors on systemic inflammation and myocardial sympathetic innervation in normotensive patients with type 2 diabetes mellitus. J Hum Hypertens 22, 191–196 (2008). https://doi.org/10.1038/sj.jhh.1002310
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1002310
Keywords
This article is cited by
-
Plasma levels of sRANKL and OPG are associated with atherogenic cytokines in patients with intermediate cardiovascular risk
Heart and Vessels (2017)
-
Effects of non-supervised low intensity aerobic excise training on the microvascular endothelial function of patients with type 1 diabetes: a non-pharmacological interventional study
BMC Cardiovascular Disorders (2016)
-
Association Between IL-6 Concentration and Diabetes-Related Variables in DM1 Patients with and without Microvascular Complications
Inflammation (2013)